(Total Views: 532)
Posted On: 09/24/2024 7:15:51 PM
Post# of 148870
RE: Resmetirom VS Liver Fibrosis
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
"Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).
https://www.nejm.org/doi/10.1056/NEJMoa230900...20placebo).
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
"Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo).
https://www.nejm.org/doi/10.1056/NEJMoa230900...20placebo).
(3)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
